Loop Capital analyst Timothy Greaves lowered the firm’s price target on Ardent Health (ARDT) to $17 from $19 and keeps a Buy rating on the shares. The company has reported disappointing results and a downward guidance due to an increase in payer denial rates and escalating cost pressures during the quarter, the analyst tells investors in a research note. Ardent management is tackling the challenges related to costs and margins through its IMPACT program however, which aims to reduce expenses and enhance revenue cycle efficiencies, the firm added.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health price target lowered to $13 from $21 at Truist
- Ardent Health price target lowered to $12 from $19 at Goldman Sachs
- Ardent Health price target lowered to $17 from $21 at Stephens
- Cautious Hold on Ardent Health Partners Amidst Guidance Cuts and Competitive Disadvantages
- Ardent Health downgraded to Equal Weight from Overweight at Morgan Stanley